Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
16.96 USD | -1.28% | +9.76% | +13.20% |
06-18 | Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Ahead of Speeches by Fed Officials | MT |
06-14 | Oppenheimer Adjusts UroGen Pharma Price Target to $40 From $32, Maintains Outperform Rating | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.20% | 621M | |
+16.47% | 122B | |
+19.75% | 115B | |
+21.22% | 26.64B | |
-23.61% | 19.91B | |
-17.47% | 16.32B | |
-45.95% | 15.52B | |
-18.36% | 15.49B | |
+62.76% | 14.83B | |
+2.11% | 13.67B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Transcript : UroGen Pharma Ltd., Q1 2023 Earnings Call, May 11, 2023